What Is Etamycin? Definition and What Research Reports

Etamycin is a naturally occurring cyclic depsipeptide antibiotic produced by soil- and marine-derived Streptomyces bacteria, and it is described in the literature as a member of the streptogramin family of antibacterial natural products (PMID 20339399). The name is sometimes used interchangeably with viridogrisein, an older designation for the same molecule. Structurally, etamycin is not a conventional linear peptide: it is a macrocyclic depsipeptide, meaning the ring is closed through both amide (peptide) bonds and at least one ester (lactone) bond, and it incorporates unusual, non-proteinogenic building blocks rather than the standard twenty amino acids. Because of that peptide-derived architecture, it is catalogued alongside other nonribosomal peptide natural products in glossaries and databases that cover peptide chemistry.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medicines or laboratory work. Nothing here describes a protocol, and no human use is implied.

Molecule class and origin at a glance

Where etamycin comes from

Etamycin is a microbial secondary metabolite. Actinomycetes of the genus Streptomyces assemble this kind of molecule using nonribosomal peptide synthetase enzymes, which string together amino-acid and hydroxy-acid units without using messenger RNA or the ribosome. That biosynthetic route explains why the finished molecule contains residues that never appear in ordinary proteins, and why it is macrocyclic and resistant to the proteases that rapidly clear linear peptides.

Marine sediment and invertebrate-associated Streptomyces strains have been a recurring source. In a 2011 natural-products report, researchers described the isolation of three new antibacterial depsipeptides, fijimycins A–C, which the authors classified as etamycin-class compounds recovered from a marine-derived Streptomyces sp. (PMID 21745747). That paper illustrates a common pattern in the field: etamycin itself serves as the structural reference point against which newly discovered relatives are named and compared.

How the term is used in peptide research

In peptide-focused literature and glossaries, "etamycin" is used in three distinct ways:

• As a structural archetype. "Etamycin-class" describes depsipeptides that share its macrocyclic scaffold and characteristic residues, as in the naming of fijimycins A–C (PMID 21745747).
• As a screening hit. Etamycin appears repeatedly as a compound identified by phenotypic screening of natural-product libraries against difficult bacterial pathogens (PMID 30995807).
• As a class exemplar in antibiotic pharmacology. It is cited as a streptogramin, the family that also includes the virginiamycin and pristinamycin components (PMID 20339399).

It is worth separating etamycin from the category of compounds most readers associate with the word "peptide" — synthetic analogues of human hormones and signalling peptides. Etamycin is not a hormone analogue, not a signalling molecule for human receptors, and not a metabolic or regenerative agent. It belongs to the antibacterial natural-product literature, and every verified study summarised below is a microbiology paper.

What the published literature reports

Mycobacteria

A 2019 screening paper in Molecules reported the discovery of nosiheptide, griseoviridin and etamycin as potent anti-mycobacterial agents active against Mycobacterium avium complex, the slow-growing nontuberculous mycobacteria most often implicated in chronic pulmonary infection (PMID 30995807). The study positioned these three natural products as candidates worth further laboratory characterisation rather than as finished therapies.

A 2020 paper in the International Journal of Molecular Sciences identified etamycin as a novel inhibitor of Mycobacterium abscessus, a rapidly growing nontuberculous mycobacterium recognised for broad intrinsic drug resistance (PMID 32967077). Researchers reported inhibitory activity in laboratory assays against this organism, which is the context in which the compound is most frequently cited today.

Drug-resistant staphylococci

A 2010 report in The Journal of Antibiotics described the activity of the streptogramin antibiotic etamycin against methicillin-resistant Staphylococcus aureus (PMID 20339399). The 2011 fijimycins paper likewise reported antibacterial activity for the etamycin-class depsipeptides it characterised from a marine Streptomyces strain (PMID 21745747). Taken together, the two reports place etamycin in the discovery-stage literature on Gram-positive resistant pathogens.

Scope of the evidence

All four verified reports are laboratory studies of antibacterial activity or natural-product isolation and structure determination. None of them is a human clinical trial, and none establishes a dose, a treatment schedule or an outcome in people. Specific concentration values, strain panels and assay conditions are stated in the original papers; readers who need those numbers should consult the primary sources linked in the references rather than rely on secondary summaries.

Safety and Adverse Events: What Studies Report

The verified literature on etamycin does not contain human safety data. The 2019 and 2020 mycobacterial papers were laboratory antibacterial investigations (PMID 30995807, PMID 32967077), and the 2010 and 2011 reports were an in vitro activity study and a natural-product isolation study respectively (PMID 20339399, PMID 21745747). Because no clinical adverse-event dataset appears among these sources, no tolerability profile, no contraindication list and no drug-interaction profile can be summarised from them. The absence of reported adverse events in in vitro work is not evidence of safety; it reflects the fact that such studies do not measure it.

Common points of confusion

• Etamycin is not erythromycin. The names look similar in search results, but erythromycin is a macrolide and an approved human antibiotic, while etamycin is a streptogramin-class depsipeptide described in the research literature (PMID 20339399).
• Etamycin is not a research peptide of the hormone-analogue type. It has no reported endocrine or metabolic application in the verified literature.
• "Etamycin-class" is a structural label, not a claim of equivalence. Fijimycins A–C were named for their structural relationship to etamycin, not because they share identical properties (PMID 21745747).
• Activity against a pathogen in culture is not a treatment. The mycobacterial reports describe inhibition in laboratory systems (PMID 32967077).

Summary of the definition

Etamycin: a Streptomyces-derived macrocyclic depsipeptide of the streptogramin family, also called viridogrisein, containing non-proteinogenic residues and studied in vitro as an antibacterial agent. The published record cited here reports activity against Mycobacterium avium complex (PMID 30995807), inhibition of Mycobacterium abscessus (PMID 32967077) and activity against methicillin-resistant Staphylococcus aureus (PMID 20339399), with related depsipeptides isolated from marine strains (PMID 21745747). This entry is definitional and describes what researchers reported; it is not guidance of any kind.

References

• Etamycin as a Novel Mycobacterium abscessus Inhibitor (International Journal of Molecular Sciences, 2020)
• Discovery of Nosiheptide, Griseoviridin, and Etamycin as Potent Anti-Mycobacterial Agents against Mycobacterium avium Complex (Molecules, 2019)
• Fijimycins A-C, three antibacterial etamycin-class depsipeptides from a marine-derived Streptomyces sp (Bioorganic & Medicinal Chemistry, 2011)
• Activity of the streptogramin antibiotic etamycin against methicillin-resistant Staphylococcus aureus (The Journal of Antibiotics, 2010)